although
convent
antimicrobi
drug
view
miracul
cureal
past
year
increas
antimicrobi
drug
resist
requir
major
rapid
intervent
howev
develop
novel
still
convent
system
antimicrobi
agent
singl
mode
site
action
allevi
situat
probabl
matter
time
agent
also
becom
ineff
ectiv
continu
produc
new
agent
base
notion
unaccept
increas
need
altern
approach
problem
contrast
lightactiv
molecul
call
photoantimicrobi
act
local
via
insitu
product
highli
reactiv
oxygen
speci
simultan
attack
variou
biomolecular
site
pathogen
target
therefor
er
multipl
variabl
site
action
nonspecifi
citi
target
circumv
convent
mechan
resist
inhibit
develop
resist
agent
photoantimicrobi
therapi
safe
easi
implement
unlik
convent
agent
activ
spectrum
photoantimicrobi
cover
bacteria
fungi
virus
protozoa
howev
clinic
trial
new
truli
broadspectrum
minim
toxic
agent
fund
research
develop
almost
nonexist
photoantimicrobi
constitut
one
way
forward
morass
drugresist
infecti
diseas
fulli
explor
person
view
rais
awar
novel
photoantimicrobi
technolog
er
viabl
altern
convent
drug
mani
relev
applic
fi
eld
could
thu
slow
pace
resist
develop
past
year
report
posit
statement
govern
region
global
health
author
fi
nalli
acknowledg
serious
antimicrobi
drug
resist
similar
statement
made
discuss
undertaken
regularlywith
plenti
wellreason
argumentsamong
scientifi
c
commun
past
year
without
appar
acknowledg
wield
legisl
power
howev
us
center
diseas
control
prevent
european
commiss
summit
nation
govern
among
industrialis
countri
spoken
one
voic
call
chang
clinic
practic
rapid
develop
new
approach
infect
control
encourag
basic
research
unfortun
recent
agreement
mean
look
forward
happi
futur
infecti
diseas
concern
desir
among
variou
strata
healthcar
providersperhap
unstat
nonethelesssimpli
fail
antimicrobi
drug
replac
brand
new
set
desir
understand
given
eas
treatment
associ
antibiot
microb
display
resist
common
belief
remain
principl
could
return
glori
day
antibiot
era
noth
chang
howev
know
microorgan
rapidli
develop
resist
varieti
costli
antimicrobi
agent
problem
larg
deriv
singl
mode
action
larg
bodi
evid
suggest
reason
matter
time
microorgan
develop
ampl
resist
improv
approach
avoid
futur
develop
resist
focu
compound
mode
action
interact
multipl
target
potenti
new
antibiot
teixobactin
appear
promis
respect
attack
altern
target
face
resist
howev
antibiot
seem
mainli
activ
gramposit
bacteria
altern
safer
effi
cient
antimicrobi
strategi
urgent
neededinclud
effi
caci
gramneg
bacteria
mycobacteria
fungal
viral
protozo
pathogen
person
view
contend
use
lightactiv
molecul
photoantimicrobi
viabl
option
deserv
fulli
explor
discuss
photoantimicrobi
use
prospect
adopt
mainstream
clinic
antimicrobi
fi
ght
convent
drug
resist
origin
report
concern
photoantimicrobi
eff
ect
publish
raab
show
inactiv
paramecium
caudatum
expos
dye
acridin
eosin
illumin
sunlight
raab
supervisor
von
tappein
jesionek
appli
approach
tumour
cell
report
result
thu
antimicrobi
anticanc
approach
photodynam
therapi
known
centuri
anticanc
photodynam
therapi
clinic
realiti
hospit
dermatolog
clinic
worldwid
includ
treatment
actin
keratosi
basal
cell
carcinoma
year
antimicrobi
photodynam
therapi
still
larg
unappreci
clinician
bodi
respons
healthcar
provis
figur
show
photoantimicrobi
discoveri
extens
convent
agent
sinc
substanti
increas
sinc
begin
socal
era
resist
basic
principl
photodynam
antimicrobi
concept
combin
visibl
near
infrar
light
person
view
oxygen
photoantimicrobi
abl
absorb
transfer
energi
electron
light
absorpt
molecular
oxygen
gener
reactiv
oxygen
speci
fi
gure
reactiv
oxygen
speci
singlet
oxygen
superoxid
anion
hydroxyl
radic
broad
spectrum
activ
destroy
numer
molecular
microbi
target
eg
protein
lipid
nucleic
acid
make
unlik
microb
develop
resist
worth
emphasis
internalis
drug
prerequisit
cell
kill
prevent
onset
resist
observ
vitro
via
repeat
subleth
photosensitis
bacteria
mechan
action
neither
select
photoantimicrobi
resist
alter
sensit
convent
antibacteri
drug
respect
effl
ux
major
class
antimicrobi
photosensitis
test
extens
vitro
array
knockout
overexpress
bacteri
effl
ux
mutant
phenothiazinium
among
photosensitis
class
test
found
effl
ux
substrat
despit
fi
nding
use
specifi
c
effl
ux
pump
inhibitor
revers
reduc
phenothiazinium
phototox
due
effl
ux
effl
ux
system
central
compon
intrins
antimicrobi
resist
photoantimicrobi
action
requir
three
compon
ie
drug
light
oxygen
phototox
eff
ect
light
subsequ
product
reactiv
oxygen
speci
constitut
default
mechan
action
thu
primari
target
resist
develop
mechan
action
gener
reactiv
oxygen
speci
ro
follow
two
altern
pathway
light
activ
given
photosensitis
ps
ps
absorb
photon
ground
state
form
excit
singlet
state
state
undergo
intersystem
cross
longerliv
triplet
state
might
interact
oxygen
two
mechan
type
gener
h
electron
transfer
excit
ps
type
triplet
state
ps
directli
undergo
energi
exchang
triplet
ground
state
oxygen
lead
format
excit
gener
ro
rapidli
react
environ
depend
localis
excit
pseg
microorgan
cell
wall
lipid
membran
peptid
nucleic
acid
ps
return
initi
state
cycl
readi
absorb
new
photon
gener
addit
ro
superoxid
anion
radic
h
hydrogen
peroxid
person
view
provid
photoantimicrobi
uniqu
competit
microbicid
advantag
potenti
pathogen
target
independ
whether
carri
sophist
effl
ux
system
must
cope
two
altern
assault
thu
minimis
substanti
possibl
resist
develop
addit
effl
ux
system
transmembran
protein
well
document
protein
highli
suscept
photodynam
eff
ect
furthermor
potenti
resist
oxid
burst
result
illumin
might
includ
enzym
superoxid
dismutas
catalas
enzym
ineff
ectiv
singlet
oxygen
inde
inactiv
consequ
exampl
staphylococcu
aureu
meticillinresist
aureu
klebsiella
pneumonia
whether
carbapenemaseposit
escherichia
coli
produc
extendedspectrum
new
delhi
suscept
cation
photoantimicrobi
activ
harmless
light
fi
gure
addit
activ
gramposit
gramneg
bacteria
photoantimicrobi
eff
ectiv
fungal
viral
protozo
target
exert
kill
eff
ect
much
rapidli
convent
agent
might
take
hour
day
becom
eff
ectiv
even
suscept
strain
broadspectrum
activ
would
clearli
use
empir
treatment
emerg
undiagnos
infecti
diseas
practic
major
select
criterion
photodynam
approach
short
incub
period
photosensitis
illumin
typic
minut
favour
localis
microorgan
minimis
penetr
host
tissu
observ
sever
hour
addit
physic
control
allow
local
applic
light
rapid
uptak
target
cell
rel
host
combin
physic
target
illumin
provid
distinct
select
therapeut
advantag
photoantimicrobi
compar
convent
drug
topic
local
applic
statement
entir
appli
system
infect
next
challeng
research
frontier
photoantimicrobi
photoantimicrobi
action
furthermor
aff
ect
express
virul
factor
eg
protein
toxin
proteas
sphingomyelinas
lipopolysaccharid
caus
degrad
chemic
oxid
eff
ect
photoantimicrobi
destroy
virul
factor
extrem
import
might
present
infect
process
secret
microorgan
also
present
absenc
activ
infect
case
endotoxin
caus
sever
damag
host
photoantimicrobi
also
disrupt
mani
sophist
phenotyp
process
multidrug
resist
relat
biofi
lm
format
extracellular
slime
stationari
bacteri
growth
architectur
viabil
earli
matur
biofi
lm
addit
photoantimicrobi
action
associ
upregul
key
oxid
stress
enzym
superoxid
dismutas
induct
bacteri
heat
shock
protein
groel
dnak
caus
refold
denatur
protein
stabilis
lipid
membran
stress
concentr
appliedtyp
micromolar
rangephotoantimicrobi
harmless
host
tissu
without
light
activ
light
activ
millimolar
rang
longer
time
interv
chemic
naturea
major
compound
phenothiazinium
salt
porphyrin
phthalocyaninesth
biocompat
high
chemic
properti
also
case
natur
product
photosensitis
curcumin
approv
food
addit
ribofl
avin
vitamin
hypericin
activ
photoantimicrobi
simpl
use
lowpow
laser
lightemit
diod
convent
halogen
lamp
fi
breoptic
technolog
region
anatomi
access
mani
case
loci
infect
ear
nose
throat
gastrointestin
tract
lung
urinari
tract
bowel
could
manag
endoscop
allow
local
applic
photoantimicrobi
agent
light
even
deepseat
infect
transcutan
needl
could
deliv
photoantimicrobi
agent
light
via
fi
bre
addit
integr
plastic
optic
fi
bre
textil
structur
enabl
uniform
light
distribut
complex
geometri
human
anatomi
develop
lightemit
bandag
wearabl
lightemit
garment
also
underway
worth
rememb
therapeut
use
lightactiv
pharmaceut
rel
recent
ubiquit
dermatolog
depart
treatment
psoriasi
use
psoralen
ultraviolet
irradi
therapi
iron
combin
therapi
also
photoantimicrobi
photoantimicrobi
gener
toxic
molecul
confus
biocid
photocatalyt
mode
action
singl
photosensitis
molecul
gener
mani
molecul
singlet
oxygen
destroy
kill
microb
rapidli
much
lower
concentr
biocid
clinic
manag
simpli
achiev
control
dose
light
administ
furthermor
photoantimicrobi
fulfi
l
gener
criteria
new
intervent
address
antibiot
resist
crisisnam
prevent
infect
resist
preserv
avail
antibiot
slow
resist
develop
microbeattack
treatment
diminish
potenti
drive
resist
toxic
human
host
wouldquit
correctlyb
concern
new
antimicrobi
agent
convent
person
view
otherwis
highli
eff
ectiv
photoantimicrobi
gentian
violet
methylen
blue
clinic
system
use
peopl
centuri
excel
safeti
record
exampl
system
use
methylen
blue
extens
examin
test
convent
antimalari
agent
subsaharan
africa
system
singl
human
dose
methylen
blue
mgkg
use
convent
antimalari
trial
dose
convert
maximum
concentr
wherea
exampl
minimum
photobactericid
concentr
photoantimicrobi
invitro
aureu
e
coli
region
also
note
local
rather
system
administr
propos
moreov
heal
tissu
known
good
photodynam
therapi
make
photoantimicrobi
suitabl
choic
wound
traumat
infect
ie
acut
bacteri
skin
skin
structur
infect
addit
consider
treatment
mani
localis
infect
photoantimicrobi
photosensitis
local
administ
infect
area
red
light
deliv
diff
use
scatter
well
beyond
actual
area
infect
red
light
substanti
benefi
cial
eff
ect
stimul
heal
repair
surround
tissu
process
known
photobiomodul
lowlevel
laser
therapi
photodynam
approach
also
applic
veterinari
medicinea
requir
addit
activ
spectrum
enabl
futur
conserv
convent
antimicrobi
exampl
treatment
caseou
lymphaden
abscess
sheep
photoantimicrobi
eff
ectiv
heal
time
much
shorter
describ
convent
approach
similarli
photoantimicrobi
suitabl
remov
typic
bacteri
fungal
contamin
food
product
includ
use
product
surfac
import
given
foodborn
waterborn
diarrhoeal
diseas
kill
million
peopl
worldwid
per
year
environment
applic
photodynam
antimicrobi
procedur
rang
manag
plant
pathogen
control
aquat
pathogen
fi
sh
farm
inactiv
multidrugresist
bacteria
hospit
wastewat
furthermor
use
photoantimicrobi
materi
furnish
lightactiv
surfac
might
use
strengthen
environment
infect
control
healthcar
set
use
devic
indwel
cathet
prosthes
although
mani
instrument
platform
detect
method
develop
commiss
countermeasur
biolog
warfar
agent
threat
use
biolog
agent
bioterrorist
attack
still
remain
lead
caus
global
concern
bacillu
spp
spore
suscept
photoinactiv
phenothiazinium
dye
methylen
blue
toluidin
blue
low
dose
red
light
indic
applic
anthrax
spore
decon
tamin
nevertheless
major
biolog
warfar
agent
select
respiratori
mode
transmiss
melioidosi
burkholderia
pseudomallei
glander
burkholderia
mallei
tularaemia
francisella
tularensi
pneumon
plagu
yersinia
pesti
airborn
pathogen
constitut
challeng
photoact
drug
light
deliveri
activ
fi
eld
investig
major
factor
centuri
antiinfecti
diseas
programm
infl
uenc
globalisationi
eas
transcontinent
movement
increas
number
popul
migrat
resist
develop
establish
popul
model
resourc
duli
plan
problem
mobil
popul
dissemin
infecti
diseas
previous
unseen
novel
resist
pattern
potenti
disastr
exampl
includ
outbreak
sever
acut
respiratori
syndrom
sar
caus
coronaviru
earli
global
spread
acinetobact
baumannii
infect
civilian
hospit
deal
wound
militari
personnel
concern
also
exist
drugresist
tuberculosi
could
easili
spread
enclav
former
soviet
union
africa
becom
global
problem
control
emerg
infecti
diseas
often
complic
fact
antibiot
use
indiscrimin
often
selfadminist
aff
ect
popul
consequ
microbi
strain
might
easili
acquir
resist
lower
suscept
approv
prescrib
drug
addit
potenti
transmiss
resist
phenotyp
speci
among
indigen
microbiota
howev
sinc
photoantimicrobi
truli
antimicrobi
expect
eff
ectiv
emerg
unknown
pathogen
new
resist
trait
well
establish
convent
suscept
convent
resist
speci
system
microbi
diseas
sever
term
morbid
mortal
search
system
administ
therapi
must
continu
howev
mani
situat
eff
ectiv
altern
local
approach
could
advantageouseg
patient
decolonis
treatment
burn
wound
diabet
foot
ulcer
thu
avoid
use
valuabl
system
drug
could
conserv
critic
care
also
rapidli
act
photoantimicrobi
intervent
might
help
prevent
localis
infect
becom
system
localis
infect
import
clinic
substanti
percentag
healthcareassoci
infect
origin
surgic
wound
mani
locat
skin
soft
tissu
eventu
caus
system
infect
pharmaceut
industri
produc
convent
agent
broad
rang
activ
similar
exhibit
cation
photoantimicrobi
agent
would
laud
gamechang
breakthrough
particularli
time
larg
pharmaceut
compani
substanti
reduc
presenc
fi
eld
antimicrobi
howev
impress
perform
lightactiv
technolog
wide
ignor
despit
around
quarter
centuri
encourag
experiment
clinic
studi
countless
attempt
bring
new
approach
attent
healthcar
provid
report
antimicrobi
approach
potenti
produc
similar
chang
concept
way
address
diseas
caus
microbi
infect
approach
clearli
appropri
shortag
convent
clinic
agent
worsen
antimicrobi
resist
case
tuberculosi
addit
present
resist
one
standard
drug
usual
isoniazid
increas
case
multipl
extens
drug
resist
often
associ
hiv
comorbid
multidrug
resist
extens
drug
resist
mycobacteria
shown
suscept
photoantimicrobi
vitro
thu
despit
overwhelm
evid
clinic
trial
tabl
three
photoantimicrobi
agent
methylen
blue
toluidin
blue
indocyanin
green
far
receiv
clinic
approv
dentistri
adjuv
approach
unsurprisingli
combinatori
use
photoantimicrobi
convent
drug
receiv
consider
attent
term
infect
control
photodynam
commun
far
consist
mainli
variou
academ
group
work
toward
introduct
clinic
photoantimicrobi
without
consensu
regard
microbi
target
diseas
indic
continu
shortag
support
scarciti
grant
fundingcertainli
comparison
convent
antiinfect
researchw
provid
consensu
statement
intent
person
view
fi
rmli
believ
photodynam
antimicrobi
approach
er
enorm
potenti
save
term
conserv
essenti
convent
drug
rapid
treatment
initi
localis
infect
thu
requir
less
exposur
microbiom
select
pressur
exert
convent
antimicrobi
us
billion
forward
fund
antimicrobi
resist
programm
suggest
uk
oneil
report
wherea
us
fi
gure
billion
would
tragic
happen
fund
forthcom
current
situat
maintain
fund
goe
sole
convent
antimicrobi
develop
key
worldwid
health
organis
spoken
requir
novel
altern
approach
brave
enough
use
